Zydus Cadila seeks approval for its repurpose Hepatitis C drug for Covid-19


 

India's Cadila Healthcare Ltd has sought approval from local regulators to use a Hepatitis C drug as a treatment for COVID-19 following promising interim results from a late-stage trial, the drug maker said on Monday.

A single dose of the Hepatitis C drug when taken early could help COVID-19 patients recover faster and avoid complications seen in the advanced stages of the disease, Cadila said in a statement to stock exchanges.

About 91% of patients treated with the drug tested negative for COVID-19 in standard RT-PCR tests by day seven, compared to nearly 79% who were given the standard of care, the company said citing Phase-III clinical trial data.

The drug, known as Pegylated Interferon alpha-2b and branded as 'PegiHep' by Cadila, was originally approved for liver disease Hepatitis C and launched in India 10 years ago. It is being repurposed to treat COVID-19. Read More

Comments

Popular posts from this blog

Cafe Coffee Day names S V Ranganath as interim chairman

Kohli only Indian among Forbes highest paid athletes, Messi tops the list

Mia Khalifa engaged to beau Robert Sandberg